肽受体放射性药物治疗后的进展模式
该回顾性研究纳入2016至2024年接受PRRT的195例神经内分泌肿瘤患者,107例(54.9%)出现进展。进展后SSTR PET显示多数患者仍表达SSTR,SSTR阴性者仅4例(3.7%),SSTR PET在46.7%患者中识别出传统影像未见的进展。
要点
- PRRT后进展患者中SSTR阴性者仅3.7%,多数仍适合SSTR靶向放射性配体再治疗。
- 进展后SSTR PET在46.7%患者中识别出传统影像未发现的进展。
- 肝脏是主要进展部位(60.7%),其次为骨(25.3%)。
核心结论
- PRRT后多数进展患者仍表达SSTR,SSTR阴性疾病罕见,提示多数仍适合SSTR靶向放射性配体再治疗。
研究设计与样本
- 回顾性研究,评估2016至2024年接受PRRT的195例神经内分泌肿瘤患者,复习影像与肿瘤内科记录以判定进展。
主要发现
- 195例中107例(54.9%)出现进展,肝脏为最主要进展部位(65例,60.7%),其次为骨(27例,25.3%)。
- SSTR PET最热病灶SUVmax基线为54.3±41.0,进展后为46.0±35.5(P=0.02)。
- 进展后SSTR PET定性摄取与基线相比:相等59.7%、增高18.2%、减低19.5%,SSTR阴性4例(3.7%)。
- SSTR PET在50例(46.7%)中识别出传统影像未见的进展。
关键数值与推荐
- 进展后SSTR阴性疾病仅4例(3.7%),支持多数患者仍符合SSTR靶向放射性配体再治疗条件。
临床怎么用
- PRRT后怀疑进展时应行SSTR PET,尤其关注骨等不可测量病灶,以发现传统影像漏诊的进展。
- 进展后SSTR PET仍阳性者,可考虑SSTR靶向放射性配体再治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). It is often thought that NET progression may result in somatostatin receptor (SSTR)-negative disease because of the elimination of SSTR-positive clones. This study aimed to assess the patterns of progression and SSTR uptake in patients with NETs after peptide receptor radionuclide therapy (PRRT). Methods: In this retrospective study, we evaluated patients with NETs who received PRRT between 2016 and 2024. Imaging findings and medical oncology notes were reviewed to identify and characterize disease progression. Using postprogression SSTR PET scans, the SUVmax of the progressed lesion was measured, and qualitative radiotracer uptake was compared with baseline. Results: In total, 195 patients were treated with PRRT, and progression occurred in 107 patients (54.9%). The liver was the dominant site of progression (65 patients, 60.7%), followed by bone (27 patients, 25.3%). The mean ± SD SUVmax of the hottest lesion on SSTR PET was 54.3 ± 41.0 at baseline and 46.0 ± 35.5 after disease progression (P = 0.02). Qualitatively, postprogression SSTR PET showed equal uptake in 59.7% of patients, higher uptake in 18.2%, and reduced uptake in 19.5% compared with baseline. SSTR-negative disease was observed in 4 patients (3.7%). SSTR PET identified progression that was not seen on conventional imaging in 50 patients (46.7%). Conclusion: Most patients who experienced progression after PRRT continued to express SSTR, with a decrease in SUVmax SSTR-negative disease was rare, indicating that the majority remained eligible for retreatment with SSTR-targeted radioligands. SSTR PET identified disease progression in 46.7% of patients, emphasizing its essential role in detecting disease progression, particularly in nonmeasurable disease, such as that in bone.
引用
- Moradpour M, Moradi Tochayi A, Houshmand S, et al. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2026. PMID: 41956562. doi:10.2967/jnumed.125.270483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。